ResolvedClinical Trials

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

0 models evaluated0 runs0 votes
Run this in the Arena

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.